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Abstract
Background: The AWED (Applying Wolbachia to Eliminate Dengue) trial is a parallel, two-arm, non-blinded cluster
randomised controlled trial that is under way in Yogyakarta, Indonesia, with the aim of measuring the efficacy of
Wolbachia-infected Aedes aegypti deployments in reducing dengue incidence in an endemic setting. Enrolment
began in January 2018 and is ongoing. The original study protocol was published in April 2018. Here, we describe
amendments that have been made to the study protocol since commencement of the trial.
Methods: The key protocol amendments are (1) a revised study duration with planned end of participant enrolment
in August 2020, (2) the addition of new secondary objectives (i) to estimate serotype-specific efficacy of the Wolbachia
intervention and (ii) to compare Ae. aegypti abundance in intervention versus untreated clusters, (3) an additional
exposure classification for the per-protocol analysis where the Wolbachia exposure index is calculated using only the
cluster-level Wolbachia prevalence in the participant’s cluster of residence, (4) power re-estimation using a multinomial
sampling method that better accounts for randomness in sampling, and (5) the addition of two trial stopping rules to
address the potential for persistently low rates of virologically confirmed dengue case enrolment and Wolbachia
contamination into untreated clusters. Additional minor changes to the protocol are also described.
Discussion: The findings from this study will provide the first experimental evidence for the efficacy of
Wolbachia in reducing dengue incidence. Enrolment in the trial will conclude this year (2020) and results will
be reported shortly thereafter.
Trial registration: ClinicalTrials.gov, identifier: NCT03055585. Registered on 14 February 2017. Last updated
22 March 2020.
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Update
This update relates to the study protocol for a cluster
randomised controlled trial to evaluate the efficacy of
Wolbachia-infected mosquito deployments to reduce
dengue incidence in Yogyakarta, Indonesia: the Applying
Wolbachia to Eliminate Dengue (AWED) trial. This
update should be read in conjunction with the original
protocol publication [1]. The trial registration record on
ClinicalTrials.gov has been updated to reflect these
protocol amendments.
Study duration
A 12-month extension to the trial duration was ap-
proved by the independent data monitoring committee
(IDMC) to account for lower-than-expected dengue inci-
dence in Yogyakarta (and elsewhere in Indonesia) during
the first year of the study period. Participant enrolment
is now planned to conclude on 31 August 2020 unless
early trial termination occurs because of Wolbachia
contamination into untreated clusters or consistently
low enrolment rates of virologically confirmed dengue
(VCD) cases (see ‘Trial stopping rules’ below).
Secondary endpoints
DENV serotype-specific efficacy
The primary endpoint of the trial includes virologically
confirmed dengue virus (DENV) infections of any (or
unknown) serotype combined, based on the detection
of DENV RNA in a pan-dengue reverse transcription
polymerase chain reaction (RT-PCR) or detection of
non-structural protein 1 (NS1) antigen. We now make
explicit the use of a second serotype-specific RT-PCR
to determine the infecting DENV serotype in samples
positive in the pan-dengue PCR and to estimate
serotype-specific efficacy of the Wolbachia interven-
tion. In laboratory experiments, the degree to which
Wolbachia reduces the DENV transmission potential of
Aedes aegypti is dependent on the infecting virus sero-
type, and DENV1 transmission is least affected [2]. A
secondary analysis will estimate the serotype-specific
efficacy of Wolbachia deployments in reducing symp-
tomatic dengue virus infection with a known infecting
serotype, for each of the four serotypes in turn or as
many as are detected in the study population. The same
intention-to-treat and per-protocol analyses described
for the primary endpoint will be used here. Case popu-
lations will be restricted to each of the DENV serotypes
in turn, and the same control population will be used
as for analysis of the primary endpoint.
Zika and chikungunya
If at least 20 virologically confirmed Zika or chikun-
gunya cases are detected, a secondary analysis will esti-
mate the efficacy of Wolbachia deployments in reducing
the incidence of symptomatic virologically confirmed
Zika virus and chikungunya virus infection. No formal
analysis will be undertaken if fewer than 20 virologically
confirmed cases of Zika or chikungunya are detected.
Only a descriptive analysis of the temporal and spatial
distribution of cases will be carried out.
Notified dengue cases
A proposed method for statistical analysis was added to
the secondary endpoint of assessing the impact of
Wolbachia deployment on routine dengue case notifica-
tions. An interrupted time series analysis of monthly
dengue haemorrhagic fever (DHF) notifications by kelur-
ahan, before and after Wolbachia releases, will be used
to evaluate the impact of Wolbachia deployment on
DHF case notifications. Methods will be developed and
validated a priori to classify area-level Wolbachia expos-
ure status in a way that aligns with the administrative
(kelurahan) boundaries by which dengue cases are re-
ported. A separate statistical analysis plan will be devel-
oped for this endpoint, and the results will be reported
in a secondary publication subsequent to the publication
of the main trial results.
Aedes species abundance
The AWED trial provides an opportunity to explore
whether fitness costs associated with Wolbachia infec-
tion of Ae. aegypti that have been identified in laboratory
environments (e.g., fecundity and egg survivorship)
manifest as a lower population size of adult mosquitoes
in areas where Wolbachia is established versus untreated
areas. A secondary endpoint was added to measure and
compare the population size of adult mosquitoes in Wol-
bachia-treated versus untreated clusters using existing
data from BG trap mosquito collections. Poisson regres-
sion will be used to test the null hypothesis of no differ-
ence in the abundance of Ae. aegypti and other species
by treatment arm, incorporating BG trap as a random
effect to account for the clustered sampling of mosqui-
toes by BG trap.
Prevalence of arbovirus-infected Aedes aegypti
mosquitoes
Assessing the impact of Wolbachia deployment on the
prevalence of arbovirus-infected Ae. aegypti mosquitoes
will no longer be carried out. Findings so far indicate
that the overall prevalence of dengue virus-infected Ae.
aegypti mosquitoes is too low for this secondary object-
ive to be feasible within the resources available.
Clinical sampling procedures
In a situation where a consenting participant has already
had blood collected for clinical investigations on the day of
enrolment, a second blood sample will not be collected for
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research purposes. Rather, the residual blood sample will be
retained and used for study investigations. Two implica-
tions of this are noted: (1) the sample volume may be lower
than the usual 3mL, and (2) informed consent may be
obtained from the participant after the clinical blood
sampling has occurred (but before retrieval of the residual
sample for use in the study). This amendment was made in
response to a number of participants who were enrolled
without a blood sample, and thus no classifiable diagnostic
results to determine case/control status, due to their refusal
to have two blood samples collected in one visit, one each
for clinical diagnostic purposes and for our study.
Diagnostic algorithm
Previously, only samples that were PCR-negative for den-
gue, chikungunya and Zika were subsequently tested by
DENV NS1 enzyme-linked immunosorbent assay (ELISA).
All samples will now be tested by both RT-PCR and NS1
ELISA (Bio-Rad dengue NS1 Platelia ELISA, Bio-Rad
Laboratories, Hercules, CA, USA) (Fig. 1). All samples posi-
tive for DENV in the triplex reverse transcription polymer-
ase chain reaction (RT-PCR) will be tested in a serotype-
specific RT-PCR to determine the infecting serotype.
Per-protocol analysis
Dataset for analysis
The same participant dataset will now be used for the
intention-to-treat analysis and the per-protocol analysis
(i.e., including all participants recruited after Wolbachia
is considered established in the intervention area, de-
fined as 1 month after completion of releases in the last
cluster).
Alternative exposure classification
An additional per-protocol analysis will be conducted in
which the Wolbachia exposure index (WEI) is calculated
using only the cluster-level Wolbachia prevalence in the
participant’s cluster of residence (in the month of par-
ticipant enrolment), ignoring the participant’s recent
travel history. This recognises that dengue exposure risk
may be higher at home versus other locations, rather
than assuming an even distribution of exposure risk
across daytime hours and locations visited.
Revised statistical methods
A mixed-effects logistic regression model will be fitted,
incorporating time as a random effect and with another
random effect for cluster membership. Such models
yield an estimate, and associated confidence interval, for
the relative risk. The WEI strata will first be included as
an ordinal covariate, and the slope of the WEI variable
will be tested for a difference from zero. The WEI strata
will additionally be included as a nominal (unordered)
covariate to calculate stratum-specific incidence rate
ratios (relative to the baseline 0–0.2 stratum). This will
allow examination of a ‘dose response’ relationship. An
additional benefit of transforming WEI to a categorical
Fig. 1 Flowchart of data and sample collection procedures and diagnostic algorithm. Blue boxes indicate participant recruitment and enrolment
activities undertaken at Puskesmas clinics, including screening against inclusion/exclusion criteria, obtaining written informed consent, and
collection of demographic and travel history data and a blood sample. Pink boxes indicate the laboratory diagnostic testing to be performed at
the project laboratory (DU), the results of which (white boxes) will be used to classify participants as virologically confirmed dengue, Zika or
chikungunya (Chik) cases or arbovirus-negative controls or excluded because of an inability to exclude arbovirus infection (grey boxes) according
to the algorithm shown. This diagnostic algorithm is updated from the original version to indicate that all samples are tested by both reverse
transcriptase polymerase chain reaction (RT-PCR) and dengue virus (DENV) non-structural protein 1 (NS1) enzyme-linked immunosorbent assay
(ELISA). In the original algorithm, only samples that were PCR-negative for dengue, chikungunya and Zika were tested by NS1 ELISA
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variable is that it avoids any assumption of linearity in
the dose response relationship.
Power calculations
Statistical power for the trial was re-estimated in January
2019 using a multinomial simulation method, with a range
of sample sizes and effect sizes, as compared with the
original power estimation which used a deterministic
simulation of a range of effect sizes but with a fixed sam-
ple size. This revised method better accounts for random-
ness in sampling, including variability in the distribution
of dengue cases and non-dengue febrile patients between
clusters. This indicates that adequate power (≥80%) can
be achieved with a substantially lower sample size than
the 1000 dengue cases assumed for the original power
simulation scenario. There is more than 80% power to
detect a risk ratio (RR) of 0.5 (or smaller) with a sample of
400 VCD cases and 4 × 400 test-negative controls.
Additional simulations in September 2019 explored
the potential impact on power if a number of untreated
clusters are ‘lost’ to Wolbachia contamination. Given
400 enrolled VCD cases and a true effect size of 50%
(RR = 0.5), contamination of three or six untreated clus-
ters is expected to result in about 7% and about 14% loss
of statistical power, respectively.
Interim analysis
An interim analysis was originally planned for the mid-
point of the study (i.e., after enrolment of 500 dengue
cases from an initial target sample size of 1000). The re-
estimation of statistical power described above indicates
that the trial will be adequately powered even with a
smaller sample size, and the threshold of 500 cases is un-
likely to be reached. The multinomial sampling method
used in the power re-estimation means that it is no longer
necessary to re-calculate sample size using the observed
inter-cluster distribution of participants, as originally
stated. In November 2019, the IDMC advised that no in-
terim analysis was required.
Trial stopping rules
Additional criteria for early termination of the trial
were introduced in October 2019 in response to in-
creasing Wolbachia contamination in several untreated
clusters. The first rule addresses the possibility that a
power loss due to contamination may compromise the
intention-to-treat analysis and would see the trial stop
if five or more untreated clusters are classified as con-
taminated. A cluster will be defined as contaminated
when the cluster-level Wolbachia frequency is more
than 50% for two monthly monitoring events within a
6-month rolling window and more than 50% of the BG
traps in the cluster have detected Wolbachia during
those monitoring events.
The second rule addresses the potential for consist-
ently low rates of VCD case enrolment to make contin-
ued recruitment until August 2020 futile in terms of
increasing sample size (statistical power) and would see
the trial stop if five or fewer VCD cases are enrolled in
any 3-month rolling window (commencing 1 November
2019).
An assessment of both the Wolbachia monitoring
results and accrual of VCD cases will be made each
month. The final decision to terminate or modify the
study continues to rest with the trial steering committee
(TSC). The participant dataset for analysis will include
all those cases enrolled up until the end of the calendar
month in which the stopping rule was triggered, even if
the date the TSC endorses the decision to stop the trial
falls in the following month.
Trial status
Recruitment into the trial began in January 2018 and is
ongoing, and completion is expected by August 2020. The
current approved protocol is version 5.1 approved by
Universitas Gadjah Mada (UGM) ethics committee on 22
January 2020 and Monash University ethics committee on
31 January 2020. This update includes additional minor
amendments made in protocol version 6.0, which was
under institutional review board review in March 2020.
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